PharmAthene was formed in 2001 to meet the critical needs of this Nation and its Allies by developing biological and chemical defense products. The Company is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror. More >>

Stock Quote

PIP (Common Stock) Exchange AMEX (US Dollar) Price $0.92 Change (%)   0.03 (3.16%) Volume 72,375 Data as of 11/20/08 4:00 p.m. ET Minimum 20 minute delay Refresh quote

Recent News

More >>

PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel - 11/19/08

ANNAPOLIS, Md., Nov. 19 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has signed an agreement with... More >>

Pharmathene Reports Third Quarter 2008 Financial and Operational Results - 11/13/08

ANNAPOLIS, Md., Nov. 13 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for... More >>

PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008 - 11/06/08

ANNAPOLIS, Md., Nov. 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the third quarter of... More >>

PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference - 11/04/08

ANNAPOLIS, Md., Nov. 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (NYSE Alternext US: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that David P. Wright, President and C... More >>

Medarex And PharmAthene Announce New Therapeutic Data For Anthrax Anti-Toxin, Valortim®  - 10/28/08

- Data Presentation at 48th ICAAC / IDSA 46th Annual Meeting - PRINCETON, N.J. and ANNAPOLIS, Md., Oct. 28 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX), a leading monoclonal antibody company, and PharmAthene, Inc. (NYSE: PIP)... More >>

PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) - 10/27/08

ANNAPOLIS, Md., Oct. 27 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE ALTERNEXT US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that dosing of volunteers has begun ... More >>

PharmAthene to Present at the 7th Annual BIO Investor Forum in San Francisco - 10/23/08

ANNAPOLIS, Md., Oct. 23 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (NYSE: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that David P. Wright, President and Chief Executive Offi... More >>

PharmAthene Announces $1.6 Million Congressional Appropriation for Continued Development of Protexia® - 10/15/08

ANNAPOLIS, Md., Oct. 15 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Consolidated Security, Disaster Assistan... More >>

PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases - 10/13/08

PharmAthene Closes Strategic Equity Financing; Raises Gross Proceeds of $13.1 Million ANNAPOLIS, Md., Oct. 13 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP), a biodefense company developing medical countermeasures against biological a... More >>

PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases - 09/30/08

Panacea Biotec to Make a $13.1 Million Strategic Investment in PharmAthene ANNAPOLIS, Md., Sept. 30 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP), a biodefense company developing medical countermeasures against biological and chemica... More >>

Date Title Duration 05/13/08   Q1 2008 Pharmathene Earnings Conference Call 60 minutes 03/31/08   Q4 2007 Pharmathene Earnings Conference Call 60 minutes 03/20/08   Pharmathene Discussion of Avecia Acquisition Conference Call 60 minutes 03/18/08   Pharmathene at Cowen and Company Health Care Conference 60 minutes

2007 Annual Report

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Pharmathene, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.